Entering text into the input field will update the search result below

Cytokinetics' myosin inhibitor shows encouraging action in thickened heart muscle disorder study

Dec. 09, 2020 8:06 AM ETCytokinetics, Incorporated (CYTK) StockCYTKBy: Vandana Singh, SA News Editor
  • Interim data from Cohort 1 of Phase 2 REDWOOD-HCM study evaluating Cytokinetics' (NASDAQ:CYTK) CK-274 for hypertrophic cardiomyopathy, showed that patients experienced substantial reductions in the average resting left ventricular outflow tract gradient, a predictor of heart failure and cardiovascular death.
  • These decrease

Recommended For You

More Trending News

About CYTK Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
CYTK--
Cytokinetics, Incorporated